Interleukin-13 receptor subunit alpha-2 conjugate and its use

IL13Rα2 conjugates, including antibodies, address the challenge of targeting IL-13Rα2-expressing cancer cells by specifically binding and reducing their viability, thereby treating cancers like melanoma and colorectal cancer.

JP2026524935APending Publication Date: 2026-07-24EXELIXIS INC
0 Cites 0 Cited by

Patent Information

Application Number
JP2026501956
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-20
Filing Date
2024-07-19
Publication Date
2026-07-24

AI Technical Summary

Technical Problem

Existing treatments are inadequate for effectively targeting and eliminating IL-13Rα2-expressing cancer cells, which are overexpressed in various malignancies, including melanoma, glioma, pancreatic cancer, ovarian cancer, breast cancer, liver cancer, and renal cancer.

Method used

Development of IL13Rα2 conjugates, such as monospecific or polyspecific antibodies, that bind specifically to IL-13Rα2, allowing for the identification, reduction, and elimination of IL-13Rα2-expressing cells, including cancer cells, through methods that inhibit tumor growth and metastasis.

Benefits of technology

The IL13Rα2 conjugates provide targeted therapy by reducing the viability and proliferation of IL-13Rα2-expressing cancer cells, inhibiting tumor invasion, and treating associated diseases like melanoma, lung cancer, and colorectal cancer.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This disclosure provides IL13Rα2 conjugates (antibodies including monospecific antibodies and multispecific antibodies such as bispecific antibodies, for example) and uses thereof. In some embodiments, such conjugates to the same epitope of IL13Rα2 (or IL13Rα2:IL13 complex) (e.g., human IL13Rα2) as an antibody containing a CDR as described herein (e.g., Tables 1-3). In some embodiments, such conjugates to the same epitope of IL13Rα2 (or IL13Rα2:IL13 complex) (e.g., human IL13Rα2) as an antibody containing heavy chain variable regions and light chain variable regions as described herein (e.g., Tables 1-3).
Need to check novelty before this filing date? Find Prior Art